Related Experiment Video
Updated: Aug 15, 2026
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
[Research Advance of Microparticles in Hypercoagulation of Hemolytic Anemia-Review]
Xie Su1, Peng Cheng2, Dong-Hong Deng1
1Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Abstract:
Microparticles (MP) are small membrane vesicles released from many different cell types in response to cellular activation or apoptosis, which have the procoagulant effect. Hemolytic anemia(HA) is a type of anemia that have a short life expectancy of red blood cells due to the destruction which exceed the hematopoietic compensatory capacity of bone marrow. Sickle cell anemia(SCD), thalassemia and paroxysmal nocturnal hemoglobinuria(PNH) are all characterized by hypercoagulation and thromboembolism (TE). Research shows that MP can promote the formation of hypercoagulative state which in turn increases the risk of thromboembolism in HA. This review mainly summarized the advance research of MP in HA in the past 5 years. Moreover the relationship between the abnormal MP and hypercoagulation in HA, the impact of the related treatment to the MP, the research of MP in animal model of HA and the application of the MP-proteomics in HA are also disscussed.
Insights
Microparticles (MPs) contribute to hypercoagulation and thromboembolism risk in hemolytic anemias (HA). This review covers recent research on MPs in HA, focusing on their role, treatment impact, and diagnostic applications.
Area of Science:
- Hematology
- Cell Biology
- Biochemistry
Background:
- Microparticles (MPs) are vesicles released during cell activation or apoptosis, possessing procoagulant properties.
- Hemolytic anemias (HA), including sickle cell anemia (SCD), thalassemia, and paroxysmal nocturnal hemoglobinuria (PNH), are linked to hypercoagulation and thromboembolism (TE).
- MPs are implicated in promoting hypercoagulation and increasing TE risk in HA patients.
Purpose of the Study:
- To review recent advancements in understanding microparticles in hemolytic anemias over the past five years.
- To explore the relationship between abnormal MPs and hypercoagulation in HA.
- To discuss the impact of treatments on MP levels and the utility of MP-proteomics in HA.
Main Methods:
- Literature review focusing on research published within the last five years.
- Analysis of studies investigating the role of MPs in the pathophysiology of hemolytic anemias.
- Examination of research on MP-proteomics and animal models in the context of HA.
Main Results:
- Microparticles significantly contribute to the prothrombotic state observed in various hemolytic anemias.
- Abnormal MP levels and characteristics correlate with hypercoagulation and increased thromboembolism risk.
- Current treatments for HA may influence MP levels, highlighting potential therapeutic targets.
Conclusions:
- Microparticles are key players in the hypercoagulation associated with hemolytic anemias.
- Further research into MP-proteomics and animal models offers promising avenues for understanding and managing HA-related complications.
- Targeting microparticle formation or activity could represent a novel therapeutic strategy for reducing thromboembolism in hemolytic anemias.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.